Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
You may also be interested in...
Private Company Edition: Newpath Partners’ second fund totals $350m, Merck KGaA committed €600m to M Ventures, Eir Ventures raised €122.3m and Breakout Ventures has $112.5m. Recent financings were led by SOTIO ($317.5m), Odyssey ($218m), Avistone ($200m) and Acepodia ($109m).
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.